

Jean Marie Connors

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/691551/publications.pdf>

Version: 2024-02-01

222
papers

14,480
citations

66343

42
h-index

22166

113
g-index

226
all docs

226
docs citations

226
times ranked

19690
citing authors

#	ARTICLE	IF	CITATIONS
1	Activated Clotting Times Demonstrate Weak Correlation With Heparin Dosing in Adult Extracorporeal Membrane Oxygenation. <i>American Journal of Therapeutics</i> , 2022, 29, e385-e393.	0.9	11
2	Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. <i>Thrombosis and Haemostasis</i> , 2022, 122, 796-807.	3.4	21
3	Consensus Statement: Hemostasis Trial Outcomes in Cardiac Surgery and Mechanical Support. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1026-1035.	1.3	9
4	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	5.9	9
5	Interpreting recent clinical studies for COVID-19: A continual process with more new data. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, 41, 101016.	1.4	3
6	Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. <i>Minerva Medica</i> , 2022, 112, .	0.9	7
7	Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management. <i>EClinicalMedicine</i> , 2022, 44, 101276.	7.1	21
8	Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population-based analysis in response to <sc>CVS</sc> 2022 formulary changes. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	3
9	Clinical predictors of <sc>COVID</sc>-19 severity and bleeding in the <sc>ACTIV4B COVID</sc>-19 outpatient thrombosis prevention trial. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	4
10	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	5.9	43
11	Thromboinflammation and Antithrombotics in COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1234.	7.4	9
12	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. <i>European Journal of Cancer</i> , 2022, 165, 136-145.	2.8	11
13	Optimization of DOAC management services in a centralized anticoagulation clinic. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12696.	2.3	10
14	Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer. <i>Thrombosis Research</i> , 2022, 213, S77-S83.	1.7	1
15	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	6.1	15
16	A Review of Direct-acting Oral Anticoagulants and Their Use in Solid Organ Transplantation. <i>Transplantation</i> , 2022, 106, 2143-2154.	1.0	1
17	A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12739.	2.3	11
18	Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more. <i>Lancet Haematology</i> , 2022, 9, e551-e553.	4.6	3

#	ARTICLE	IF	CITATIONS
19	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. <i>Lancet Oncology</i> , The, 2022, 23, e334-e347.	10.7	138
20	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	3.8	100
21	Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2226-2236.	3.8	23
22	A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. <i>European Urology Focus</i> , 2021, 7, 1130-1136.	3.1	13
23	A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. <i>Haematologica</i> , 2021, 106, 1148-1157.	3.5	49
24	Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 405-412.	2.1	3
25	Andexanet Alfa Use in Cardiac Surgical Patients: A Xa Inhibitor and Heparin Reversal Agent. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 265-266.	1.3	12
26	Update on Guidelines for the Management of Cancer-Associated Thrombosis. <i>Oncologist</i> , 2021, 26, e24-e40.	3.7	76
27	Prediction and Prevention of Cancer-Associated Thromboembolism. <i>Oncologist</i> , 2021, 26, e2-e7.	3.7	33
28	Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps. <i>Oncologist</i> , 2021, 26, e17-e23.	3.7	12
29	Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. <i>Oncologist</i> , 2021, 26, e8-e16.	3.7	31
30	Clinical Significance of CBC and WBC Morphology in the Diagnosis and Clinical Course of COVID-19 Infection. <i>American Journal of Clinical Pathology</i> , 2021, 155, 364-375.	0.7	61
31	NATF Cancer-Associated Thrombosis Project: Introduction. <i>Oncologist</i> , 2021, 26, e1.	3.7	2
32	Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new again. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 6-7.	4.9	9
33	Recent advances in the research and management of sepsis-associated DIC. <i>International Journal of Hematology</i> , 2021, 113, 24-33.	1.6	46
34	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. <i>International Journal of Hematology</i> , 2021, 113, 330-336.	1.6	16
35	Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants. <i>Postgraduate Medicine</i> , 2021, 133, 508-516.	2.0	4
36	Harnessing Twitter to empower scientific engagement and communication: The ISTH 2020 virtual congress experience. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 253-260.	2.3	8

#	ARTICLE	IF	CITATIONS
37	Thrombosis and Coronavirus Disease 2019: Controversies and (Tentative) Conclusions. <i>Clinical Infectious Diseases</i> , 2021, 73, 2294-2297.	5.8	7
38	Post-acute COVID-19 syndrome. <i>Nature Medicine</i> , 2021, 27, 601-615.	30.7	3,051
39	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1003-1011.	2.5	12
40	Intracerebral haemorrhage in patients with brain metastases receiving therapeutic anticoagulation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 655-661.	1.9	11
41	Anesthetic Management of Von Willebrand Disease in Pregnancy: A Retrospective Analysis of a Large Case Series. <i>Anesthesia and Analgesia</i> , 2021, 133, 1244-1250.	2.2	7
42	Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 22-29.	2.1	0
43	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	2.8	150
44	Management of therapeutic unfractionated heparin in COVID-19 patients: A retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12521.	2.3	3
45	Anticoagulation in COVID-19: reaction to the ACTION trial. <i>Lancet, The</i> , 2021, 397, 2226-2228.	13.7	14
46	Heparin-induced thrombocytopenia in end-stage renal disease: Reliability of the PF4-heparin ELISA. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12573.	2.3	3
47	Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis. <i>Thrombosis Research</i> , 2021, 203, 57-60.	1.7	8
48	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2751-2759.	3.8	18
49	COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 29-35.	1.3	37
50	Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1226-1237.	7.1	47
51	When to use anticoagulation in COVID-19. <i>Thrombosis Research</i> , 2021, 204, 136-137.	1.7	1
52	A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment. <i>Postgraduate Medicine</i> , 2021, 133, 71-79.	2.0	6
53	Heparin Resistance – Clinical Perspectives and Management Strategies. <i>New England Journal of Medicine</i> , 2021, 385, 826-832.	27.0	83
54	The COVID-19 TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	3.8	23

#	ARTICLE	IF	CITATIONS
55	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3080-3089.	3.8	13
56	Thromboinflammatory findings and clinical predictors of mortality in vaccine-induced immune thrombotic thrombocytopenia. <i>European Heart Journal</i> , 2021, 42, 4073-4076.	2.2	1
57	Factor XI Deficiency. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1157-1169.	2.2	35
58	Stability of Alteplase for Catheter-Directed, Ultrasound-Facilitated Thrombolysis. <i>Blood Advances</i> , 2021, 5, 5283-5289.	5.2	1
59	JTH in clinic: A new series for the practicing clinician. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 51-51.	3.8	0
60	Rivaroxaban-calibrated chromogenic anti-Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12594.	2.3	0
61	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1703.	7.4	186
62	Evaluation of anticoagulation re-initiation practices following reversal of factor Xa inhibitors with andexanet alfa or 4F-PCC in patients with major bleeding events. <i>Thrombosis Update</i> , 2021, 5, 100076.	0.9	1
63	Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2021, 20, 103-107.	0.5	1
64	Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. <i>Blood Cancer Journal</i> , 2021, 11, 176.	6.2	13
65	Direct Oral Anticoagulant Versus Low Molecular Weight Heparin for the Treatment of Cancer-Associated Thromboembolism: 2021 Updated Meta-Analysis of Randomized Controlled Trials. <i>Blood</i> , 2021, 138, 668-668.	1.4	2
66	High Incidence of Bleeding Found with Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients. <i>Blood</i> , 2021, 138, 3632-3632.	1.4	3
67	Comparison of 4F-PCC in obese and nonobese patients with life-threatening bleeding or requiring emergent surgery. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12624.	2.3	2
68	Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. <i>Haematologica</i> , 2021, , .	3.5	0
69	Using Plasma and Prothrombin Complex Concentrates. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 032-037.	2.7	9
70	Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer. <i>European Urology</i> , 2020, 77, 388-390.	1.9	3
71	Cancer-associated thrombosis: Where do we stand?. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e73.	0.9	4
72	Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. <i>Gastroenterology</i> , 2020, 158, 1346-1358.e4.	1.3	48

#	ARTICLE	IF	CITATIONS
73	The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents. <i>TH Open</i> , 2020, 04, e288-e299.	1.4	23
74	The authors reply. <i>Critical Care Medicine</i> , 2020, 48, e989-e990.	0.9	0
75	Anticoagulation in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1675-1678.	27.0	46
76	Management of Cancer-Associated Thrombosis: An Evolving Area. <i>Cancers</i> , 2020, 12, 2999.	3.7	1
77	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. <i>Leukemia Research</i> , 2020, 98, 106459.	0.8	16
78	First view of the TESEO registry: From snapshots come photo albums. <i>European Journal of Internal Medicine</i> , 2020, 78, 30-31.	2.2	0
79	Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3174-3183.	3.8	22
80	Venous thromboembolism in the hormonal milieu. <i>Current Opinion in Hematology</i> , 2020, 27, 327-332.	2.5	3
81	VTE in ICU Patients With COVID-19. <i>Chest</i> , 2020, 158, 2130-2135.	0.8	76
82	Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients. <i>Cancers</i> , 2020, 12, 1958.	3.7	21
83	ISTH DIC subcommittee communication on anticoagulation in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2138-2144.	3.8	69
84	Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 158-160.	2.1	0
85	The authors reply. <i>Critical Care Medicine</i> , 2020, 48, e1160-e1161.	0.9	7
86	Transgender health and haematology—a matter of respect. <i>Lancet Haematology</i> , 2020, 7, e367.	4.6	1
87	Approach to the Patient with COVID-19-Associated Thrombosis: A Case-Based Review. <i>Oncologist</i> , 2020, 25, e1500-e1508.	3.7	2
88	The coagulopathy, endotheliopathy, and vasculitis of COVID-19. <i>Inflammation Research</i> , 2020, 69, 1181-1189.	4.0	302
89	Coagulopathy of Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1358-1364.	0.9	412
90	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	16.8	26

#	ARTICLE	IF	CITATIONS
91	Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2020, 19, 178-186.	0.5	1
92	Coagulopathy of COVID-19 and antiphospholipid antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, .	3.8	72
93	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , 2020, 133, 1-27.	1.5	18
94	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1859-1865.	3.8	547
95	COVID-19 and its implications for thrombosis and anticoagulation. <i>Blood</i> , 2020, 135, 2033-2040.	1.4	1,892
96	Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 518-525.	0.6	34
97	The unique characteristics of COVID-19 coagulopathy. <i>Critical Care</i> , 2020, 24, 360.	5.8	366
98	Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 562-568.	2.3	19
99	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1599-1607.	27.0	658
100	More on Venous Thrombosis during Spaceflight. <i>New England Journal of Medicine</i> , 2020, 382, 1381-1382.	27.0	4
101	Prothrombin Complex Concentrate for Warfarin Reversal in Patients with Continuous-Flow Left Ventricular Assist Devices: A Narrative Review. <i>ASAIO Journal</i> , 2020, 66, 482-488.	1.6	15
102	Running thin: implications of a heparin shortage. <i>Lancet, The</i> , 2020, 395, 534-536.	13.7	20
103	Thromboinflammation and the hypercoagulability of COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1559-1561.	3.8	529
104	Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1497-1506.	1.1	46
105	Assessing and Reversing the Effect of Direct Oral Anticoagulants on Coagulation. <i>Anesthesiology</i> , 2020, 133, 223-232.	2.5	2
106	The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 278-284.	3.8	26
107	Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 402-402.	1.6	0
108	Venous thromboembolism incidence in hematologic malignancies. <i>Blood Reviews</i> , 2019, 33, 24-32.	5.7	69

#	ARTICLE	IF	CITATIONS
109	Low-intensity anti-coagulation using Vitamin K antagonists and Factor X activity: A validation analysis of the MAGENTUM-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 668-669.	0.6	1
110	Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy?. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1973-1978.	3.8	17
111	Thromboprophylaxis Strategies in Acute Medically Ill Patients. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 118-126.	1.5	0
112	Coordinating emergent procedures after andexanet alfa. <i>American Journal of Hematology</i> , 2019, 94, E278-E282.	4.1	9
113	<p>Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 175-186.	2.3	19
114	Transgender patients and the role of the coagulation clinician. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1790-1797.	3.8	25
115	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
116	Anticoagulation for Subsegmental Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2019, 381, 1171-1174.	27.0	11
117	Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961987603.	1.7	20
118	Overcoming barriers to integrating direct oral anticoagulants into existing anticoagulation management services. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 136-137.	2.3	2
119	Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 382-386.	2.1	7
120	Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 806-816.	0.6	61
121	Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to dâ€dimer results; A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1144-1152.	3.8	34
122	Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis. <i>Chest</i> , 2019, 155, 1226-1233.	0.8	14
123	Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983736.	1.7	10
124	Derivation and Validation of Age- and Body Mass Index-Adjusted Weight-Based Unfractionated Heparin Dosing. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983348.	1.7	4
125	Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report. <i>A&A Practice</i> , 2019, 13, 271-273.	0.4	30
126	Stepped-wedge randomised trial to evaluate population health intervention designed to increase appropriate anticoagulation in patients with atrial fibrillation. <i>BMJ Quality and Safety</i> , 2019, 28, 835-842.	3.7	13

#	ARTICLE	IF	CITATIONS
127	The next(gen) step in coagulation testing. <i>Blood</i> , 2019, 134, 2002-2003.	1.4	1
128	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. <i>Blood Advances</i> , 2019, 3, 3770-3779.	5.2	58
129	Andexanet Alfa (Andexxa) Formulary Review. <i>Critical Pathways in Cardiology</i> , 2019, 18, 66-71.	0.5	17
130	Thrombophilia evaluation in pulmonary embolism. <i>Current Opinion in Cardiology</i> , 2019, 34, 603-609.	1.8	9
131	Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis. <i>Journal of Clinical Neuroscience</i> , 2019, 62, 188-194.	1.5	1
132	Resource utilization and hospital readmission associated with gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 375-383.	2.1	2
133	Postoperative bridging anticoagulation and left ventricular assist system thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 57-66.	2.1	2
134	Andexanet alfa—The first 150 days. <i>American Journal of Hematology</i> , 2019, 94, E21-E24.	4.1	26
135	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2019, 134, 4172-4172.	1.4	6
136	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 71-79.	2.5	9
137	A Multicenter Study of Romiplostim to Treat Chemotherapy-Induced Thrombocytopenia in Solid Tumors and Lymphoid Malignancies. <i>Blood</i> , 2019, 134, 389-389.	1.4	8
138	Development of an Outpatient Guideline for Optimal Anticoagulation Bridging in Patients With Durable Mechanical Circulatory Support. <i>Critical Pathways in Cardiology</i> , 2018, 17, 32-37.	0.5	2
139	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. <i>Blood</i> , 2018, 131, 2151-2160.	1.4	62
140	Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump—the MAGENTUM 1 study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 579-586.	0.6	128
141	Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulability. <i>American Journal of Hematology</i> , 2018, 93, E156-E158.	4.1	8
142	The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 306-314.	2.1	31
143	Expanding anticoagulation management services to include direct oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 274-280.	2.1	26
144	Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 81-83.	2.1	13

#	ARTICLE	IF	CITATIONS
145	Description and Evaluation of the Implementation of a Weight-Based, Nurse-Driven Heparin Nomogram in a Tertiary Academic Medical Center. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 248-253.	1.7	15
146	Use of systemic bivalirudin with catheter-directed thrombolysis in a patient with heparin-induced thrombocytopenia: A case report. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, E17-E20.	1.7	8
147	Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2018, 379, 1846-1850.	27.0	66
148	Betrixaban in the prevention of venous thromboembolism in medically ill patients. <i>Future Cardiology</i> , 2018, 14, 455-470.	1.2	2
149	Hemorrhagic Highs from Synthetic Cannabinoids – A New Epidemic. <i>New England Journal of Medicine</i> , 2018, 379, 1275-1277.	27.0	8
150	Response by Netuka et al regarding the article “Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump—the MAGENTUM 1 study” <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1279-1280.	0.6	0
151	Testing and monitoring direct oral anticoagulants. <i>Blood</i> , 2018, 132, 2009-2015.	1.4	60
152	Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 180-185.	2.1	16
153	Evaluation of Compliance with a Weight-based Nurse-driven Heparin Nomogram in a Tertiary Academic Medical Center. <i>Critical Pathways in Cardiology</i> , 2018, 17, 83-87.	0.5	5
154	The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis. <i>Cancers</i> , 2018, 10, 271.	3.7	33
155	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1668-1678.	3.4	121
156	Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation. <i>PLoS ONE</i> , 2018, 13, e0194193.	2.5	29
157	Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC). <i>Oncotarget</i> , 2018, 9, 26990-26999.	1.8	13
158	Daratumumab for Delayed Red Cell Engraftment after Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 2545-2545.	1.4	0
159	Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism. <i>Blood</i> , 2018, 132, 2506-2506.	1.4	6
160	Comparison of an IgG-Specific Enzyme-Linked Immunosorbent Assay Cutoff of 0.4 Versus 0.8 and 1.0 Optical Density Units for Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 282-286.	1.7	7
161	The Role of Anticoagulants in the Prevention of Pregnancy Complications. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 116-123.	1.7	8
162	Development of a Predictive Nomogram for the Change in PT/INR Upon Discontinuation of Bivalirudin as a Bridge to Warfarin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 487-493.	1.7	5

#	ARTICLE	IF	CITATIONS
163	Prospective evaluation of a bivalirudin to warfarin transition nomogram. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 498-504.	2.1	3
164	Direct Thrombin Inhibitor for LVAD Thrombosis: A Closer Look. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 405-409.	1.7	8
165	Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, 1185-1191.	3.5	31
166	Idarucizumab for urgent reversal of dabigatran for heart transplant: A case report. <i>American Journal of Hematology</i> , 2017, 92, E34-E35.	4.1	15
167	Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. <i>Thrombosis Research</i> , 2017, 150, 53-58.	1.7	9
168	Thrombophilia Testing and Venous Thrombosis. <i>New England Journal of Medicine</i> , 2017, 377, 1177-1187.	27.0	269
169	Pregnancy outcomes in inherited bone marrow failure syndromes. <i>Blood</i> , 2017, 130, 1671-1674.	1.4	12
170	Thrombophilia Testing and Venous Thrombosis. <i>New England Journal of Medicine</i> , 2017, 377, 2297-2298.	27.0	28
171	Whole-exome sequencing in evaluation of patients with venous thromboembolism. <i>Blood Advances</i> , 2017, 1, 1224-1237.	5.2	55
172	Anticoagulation and Enzalutamide: Caution Over Convenience. <i>Journal of Oncology Practice</i> , 2017, 13, 728-729.	2.5	4
173	Aminocaproic acid for the management of bleeding in patients on extracorporeal membrane oxygenation: Four adult case reports and a review of the literature. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2016, 45, 232-236.	1.6	21
174	Direct Oral Anticoagulants in Clinical Practice. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, ix-x.	2.2	0
175	Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis. <i>Pharmacotherapy</i> , 2016, 36, e160-e165.	2.6	35
176	Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 616-622.	2.1	17
177	Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 860-867.	0.6	121
178	Idarucizumab (Praxbind) Formulary Review. <i>Critical Pathways in Cardiology</i> , 2016, 15, 77-81.	0.5	19
179	On Target. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	2
180	Prothrombin Complex Concentrate for Non-Bleeding Urgent Warfarin Reversal in Ventricular Assist Device Patients Undergoing Heart Transplantation. <i>Current Emergency and Hospital Medicine Reports</i> , 2016, 4, 93-97.	1.5	3

#	ARTICLE	IF	CITATIONS
181	Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. American Journal of Medicine, 2016, 129, 1198-1204.	1.5	121
182	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 32-67.	2.1	243
183	Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center. Journal of Emergency Medicine, 2016, 50, 7-13.	0.7	33
184	Post-Operative Anticoagulation and the Incidence of Left Ventricular Assist Device Thrombosis. Blood, 2016, 128, 2620-2620.	1.4	0
185	Prothrombin complex concentrate for factor VII replacement in a patient undergoing left ventricular assist device implantation with factor VII deficiency. American Journal of Hematology, 2015, 90, E185.	4.1	1
186	Anticoagulation management of left ventricular assist devices. American Journal of Hematology, 2015, 90, 175-178.	4.1	17
187	Antidote for Factor Xa Anticoagulants. New England Journal of Medicine, 2015, 373, 2471-2472.	27.0	34
188	Prothrombin Complex Concentrate (4PCC): A Review of its Use in Reversal of Vitamin K Antagonists. Current Emergency and Hospital Medicine Reports, 2015, 3, 50-54.	1.5	0
189	Implementation of a Hemostatic and Antithrombotic Stewardship program. Journal of Thrombosis and Thrombolysis, 2015, 40, 379-382.	2.1	35
190	Regulatory, legislative, and policy updates with anticoagulant use. Journal of Thrombosis and Thrombolysis, 2015, 39, 273-287.	2.1	0
191	Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 632-638.	1.7	10
192	D-Dimer Testing to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Stop Anticoagulant Therapy. Annals of Internal Medicine, 2015, 162, 27-34.	3.9	128
193	Cost-Effectiveness Analysis of Warfarin Versus Low-Molecular Weight Heparin for the Treatment of Malignancy-Associated Venous Thromboembolism. Blood, 2015, 126, 746-746.	1.4	9
194	Venous Thromboembolism Is Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 742-742.	1.4	0
195	Prophylaxis against Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, 2014, 371, 1262-1264.	27.0	4
196	Type A Aortic Dissection in a Patient on Dabigatran: Hemostasis Post Circulatory Arrest. Annals of Thoracic Surgery, 2014, 98, 2215-2216.	1.3	13
197	New Oral Anticoagulants and the Cancer Patient. Oncologist, 2014, 19, 82-93.	3.7	180
198	Prophylaxis against Venous Thromboembolism in Ambulatory Patients with Cancer. New England Journal of Medicine, 2014, 370, 2515-2519.	27.0	44

#	ARTICLE	IF	CITATIONS
199	Hematologic disorders and continuous-flow left ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1114-1116.	0.6	4
200	Recombinant Factor VII Activated and Prothrombin Complex Concentrate Use at a Tertiary Academic Medical Center. <i>Current Emergency and Hospital Medicine Reports</i> , 2014, 2, 151-155.	1.5	0
201	Preventing pregnancy loss. <i>Blood</i> , 2014, 123, 308-310.	1.4	2
202	Dabigatran Excess: Case Report and Review of the Literature. <i>Cardiology and Therapy</i> , 2013, 2, 111-124.	2.6	8
203	Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 767-769.	27.0	13
204	Comparing clinicians'™ use of an anticoagulation management service and usual care in ambulatory oncology. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 237-245.	0.9	2
205	The Role of Thrombophilia in Pregnancy. <i>Thrombosis</i> , 2013, 2013, 1-9.	1.4	55
206	The Safety and Adherence To Prophylactic Anticoagulation During Induction Chemotherapy In Adults With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 3867-3867.	1.4	0
207	Continuing Aspirin in the Perioperative Patient. <i>Annals of Surgery</i> , 2012, 255, 820.	4.2	0
208	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, xiii-xiv.	2.2	0
209	The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. <i>British Journal of Haematology</i> , 2011, 152, 452-459.	2.5	216
210	Dabigatran. <i>Critical Pathways in Cardiology</i> , 2011, 10, 117-127.	0.5	11
211	Case 155: Lane-Hamilton Syndrome. <i>Radiology</i> , 2010, 254, 985-988.	7.3	12
212	A Bloody Mystery. <i>New England Journal of Medicine</i> , 2009, 361, 1887-1894.	27.0	13
213	Factor XI Deficiency and Obstetrical Anesthesia. <i>Anesthesia and Analgesia</i> , 2009, 108, 1882-1885.	2.2	34
214	Anesthetic Management of Seven Deliveries in Three Sisters with the May-Hegglin Anomaly. <i>Anesthesia and Analgesia</i> , 2009, 108, 1603-1605.	2.2	15
215	A Bloody Mystery. <i>New England Journal of Medicine</i> , 2009, 361, e33.	27.0	1
216	Clinical JAK2 V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations. <i>American Journal of Hematology</i> , 2008, 83, 519-520.	4.1	7

#	ARTICLE	IF	CITATIONS
217	Gestational Platelet Trends and Outcomes in Women with Myeloproliferative Disorders Characterized by Thrombocytosis. <i>Blood</i> , 2008, 112, 5251-5251.	1.4	0
218	JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations.. <i>Blood</i> , 2007, 110, 1634-1634.	1.4	0
219	Cord Blood Leptin and Insulin-Like Growth Factor Levels are Independent Predictors of Fetal Growth. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 935-938.	3.6	168
220	Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel. <i>New England Journal of Medicine</i> , 2000, 342, 1773-1777.	27.0	625
221	Graft-Versus-Tumor Induction With Donor Leukocyte Infusions as Primary Therapy for Patients With Malignancies. <i>Journal of Clinical Oncology</i> , 1999, 17, 1234-1234.	1.6	124
222	Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 253-261.	2.0	113